{"classes":[{"categories":[{"measurements":[{"comment":"Median not evaluable due to less than half the participants meeting criteria.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Median not evaluable due to less than half the participants meeting criteria.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"136"},{"groupId":"OG001","value":"125"}],"units":"Participants"}],"description":"Time to definitive extubation included participants who progressed to OS 7 at any time prior to Day 28.","dispersionType":"95% Confidence Interval","groups":[{"description":"Placebo administered orally QD with standard of care.","id":"OG000","title":"Placebo + SOC"},{"description":"4 mg baricitinib administered orally QD with standard of care.","id":"OG001","title":"Baricitinib + SOC"}],"paramType":"MEDIAN","populationDescription":"All participants randomly assigned to study intervention who were intubated at some point during the study.","reportingStatus":"POSTED","timeFrame":"Day 1 to Day 28","title":"Time to Definitive Extubation","type":"SECONDARY","unitOfMeasure":"days"}